Small study: semaglutide and tirzepatide users report fewer cravings and smaller portions
_Image credit: News-Medical_
An Italian pilot study with Queen Mary University of London followed 38 adults starting semaglutide or tirzepatide and found an average 7.2kg loss over three months, alongside fewer sweet and savoury cravings, more fullness after meals and 84% reporting much smaller portions. Fewer people regularly ate processed meat, while more ate vegetables, legumes, fish and white meat. The study was small and uncontrolled, and the authors flag the need to watch protein, fibre and fluid intake as portions shrink.
Source: News-Medical (8 Nov 2026). Image: News-Medical.